title: [Targeted therapies: the question of target detection and evaluation].
abstract: Therapeutic targeting of HER1 and HER2 receptors is now of routine use for treatment decisions of several important cancers: breast, lung, colon-rectum, head-and-neck. Whereas it is clear that target identification and quantitative HER2 evaluation is a prerequisite for the prescription of trastuzumab in breast cancer, the situation is much more complex for the EGF receptor and may be different for the various tumour types and the different targeting agents.
authors.affiliation: Centre Jean Perrin, BP392, 63011 Clermont-Ferrand Cedex. fpenault@cjp.fr
authors.forename: Frédérique
authors.initials: F
authors.lastname: Penault-Llorca
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism*; D006801:Humans; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D066246:ErbB Receptors; D009363:Neoplasm Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; C512478:EGFR protein, human